Blurbs

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Atreca (BCEL) and CSL (OtherCMXHF)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Krystal Biotech (KRYSResearch Report), Atreca (BCELResearch Report) and CSL (CMXHFResearch Report) with bullish sentiments.

Krystal Biotech (KRYS)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Krystal Biotech yesterday and set a price target of $130.00. The company’s shares closed last Monday at $82.40.

According to TipRanks.com, Livshits is a 5-star analyst with an average return of 29.0% and a 44.7% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Rocket Pharmaceuticals.

Krystal Biotech has an analyst consensus of Strong Buy, with a price target consensus of $103.67, a 26.3% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $74.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Atreca (BCEL)

In a report released yesterday, Kumaraguru Raja from Brookline Capital Markets reiterated a Buy rating on Atreca, with a price target of $17.00. The company’s shares closed last Monday at $2.28, close to its 52-week low of $1.51.

According to TipRanks.com, Raja is a 2-star analyst with an average return of 0.5% and a 35.1% success rate. Raja covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Arcturus Therapeutics, and Caladrius Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atreca with a $17.00 average price target.

CSL (CMXHF)

The company’s shares closed last Monday at $206.50.

Wheen has an average return of 10.6% when recommending CSL.

According to TipRanks.com, Wheen is ranked #4078 out of 7991 analysts.

CSL has an analyst consensus of Strong Buy, with a price target consensus of $225.90, which is a 9.4% upside from current levels. In a report issued on July 27, Wilsons also maintained a Buy rating on the stock with a price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on KRYS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos